Wire · operational-macro
FDA grants accelerated approval to neladalkib for previously treated locally advanced or ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
The FDA granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have previously received certain ALK tyrosine kinase inhibitors and chemotherapy, based on results from the ALKOVE-1 trial showing confirmed overall response rates.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your oncology biotech now faces a new competitor on FDA's fast track in ALK-positive lung cancer treatment. Shift clinical and market development to factor neladalkib’s entry disrupting existing second-line therapies.
◆ Coverage
1 source · 17 Nov 2026
◆ Related on Wire
◆ Topics